DUBLIN, Oct. 24, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company committed to improving outcomes and meeting critical needs in infectious diseases, will present new data from its anti-infectives portfolio as a part of 23 presentations at the upcoming IDWeek 2016, taking place Oct. 26-30, 2016, in New Orleans.
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
Presentations will feature microbiology, clinical and health outcomes and economics data, including two oral presentations evaluating patient risk factors for carbapenem-resistant Enterobactericeae (CRE) and timing of appropriate therapy in patients with serious infections, as well as other poster presentations addressing the cost of infections due to multi-drug resistant Gram-negative pathogens and acute bacterial skin and skin structure infections (ABSSSI). Additional data will highlight AVYCAZ® (ceftazidime and avibactam) clinical efficacy and susceptibility in certain difficult-to-treat pathogens; DALVANCE® (dalbavancin) pediatric safety and in vitro activity in Gram-positive pathogens causing ABSSSI; and TEFLARO® (ceftaroline fosamil) clinical outcomes and in vitro activity in Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
"The diverse range of data presented at IDWeek underscore the burden to patients and the healthcare system that can result from a variety of serious infections," said David Nicholson, Ph.D., Chief R&D Officer, Allergan. "Allergan remains committed to ongoing research and development of its portfolio, as well as providing physicians with education and surveillance data that may improve clinical outcomes for patients."
The scheduled times and titles of all the presentations are as follows:
Oral Presentations
Saturday, October 29, 10:56 – 11:09 a.m. CT
Saturday, October 29, 11:22 – 11:35 a.m. CT
Poster Presentations
AVYCAZ (ceftazidime and avibactam)
Thursday, October 27, 12:30 – 2 p.m. CT
Friday, October 28, 12:30 – 2 p.m. CT
Saturday, October 29, 12:30 – 2 p.m. CT
DALVANCE (dalbavancin)
Friday, October 28, 12:30 – 2 p.m. CT
Saturday, October 29, 12:30 – 2 p.m. CT
TEFLARO (ceftaroline fosamil)
Friday, October 28, 12:30 – 2 p.m. CT
Saturday, October 29, 12:30 – 2 p.m. CT
Clinical and Health Outcomes and Economics Data
Thursday, October 27, 12:30 – 2 p.m. CT
Friday, October 28, 12:30 – 2 p.m. CT
Saturday, October 29, 12:30 – 2 p.m. CT
Full abstracts can be found on the IDWeek website at http://www.idweekinternational.com.
About AVYCAZ®
AVYCAZ is an antibiotic developed to treat certain serious Gram-negative bacterial infections. It consists of ceftazidime, a third-generation cephalosporin and established treatment for serious Gram-negative bacterial infections, and avibactam, a non-β lactam β-lactamase inhibitor.
The addition of avibactam to ceftazidime protects ceftazidime from breakdown by certain β-lactamases. AVYCAZ offers a differentiated profile in the treatment of complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) caused by designated microorganisms in patients 18 years or older through its in vitro activity against Enterobacteriaceae, including those that produce certain extended-spectrum beta-lactamases (ESBLs) and Klebsiella pneumoniae carbapenemase (KPCs), and difficult-to-treat Pseudomonas aeruginosa.
Ceftazidime and avibactam is being jointly developed with AstraZeneca. Allergan holds the rights to commercialize ceftazidime and avibactam in North America under the brand name AVYCAZ, while AstraZeneca holds the rights to commercialize the combination in the rest of the world under the brand name Zavicefta.
INDICATIONS AND USAGE
Complicated Intra-Abdominal Infections (cIAI)
AVYCAZ® (ceftazidime and avibactam), in combination with metronidazole, is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae, Klebsiella oxytoca, Citrobacter freundii complex, and Pseudomonas aeruginosa in patients 18 years or older.
Complicated Urinary Tract Infections (cUTI), including Pyelonephritis
AVYCAZ is indicated for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter koseri, Enterobacter aerogenes, Enterobacter cloacae, Citrobacter freundii, Proteus spp., and Pseudomonas aeruginosa in patients 18 years or older.
In the treatment of cUTI, as only limited clinical safety and efficacy data for AVYCAZ are currently available, reserve AVYCAZ for use in patients with cUTI who have limited or no alternative treatment options.
Usage
To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVYCAZ and other antibacterial drugs, AVYCAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
AVYCAZ is contraindicated in patients with known serious hypersensitivity to the components of AVYCAZ (ceftazidime and avibactam), avibactam-containing products, or other members of the cephalosporin class.
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
The most common adverse reactions in cIAI (incidence of ≥5% when used with metronidazole) were diarrhea (8%), nausea (7%), and vomiting (5%). In cUTI, the most common adverse reactions (incidence of ≥10%) were constipation (10%) and anxiety (10%).
Please see full Prescribing Information for AVYCAZ at www.avycaz.com.
About DALVANCE®
DALVANCE for injection is a second-generation, semi-synthetic lipoglycopeptide, which consists of a lipophilic side-chain added to an enhanced glycopeptide backbone. DALVANCE is the first and only 30-minute, one-dose treatment option for acute bacterial skin and skin structure infections (ABSSSI) that delivers a full course of IV therapy. DALVANCE can be administered as either one 1500 mg dose or as a two-dose regimen of 1000 mg followed one week later by 500 mg, each administered over 30 minutes. DALVANCE demonstrates bactericidal activity in vitro against a range of Gram-positive bacteria, such as Staphylococcus aureus (including methicillin-resistant, also known as MRSA, strains) and Streptococcus pyogenes, as well as certain other streptococcal species.
Allergan is in partnership with Angelini and Cardiome to market dalbavancin outside of US. Angelini distributes dalbavancin under the brand name Xydalba™ in several countries, which include Italy, Spain, Poland, Portugal and many Eastern European countries, including Russia and Turkey. Cardiome commercializes dalbavancin as Xydalba in the U.K, Germany, France, the Netherlands, Belgium, Nordic nations, certain other Western European nations, various Middle Eastern nations and Canada.
INDICATION AND USAGE
DALVANCE (dalbavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (including S. anginosus, S. intermedius, S. constellatus) and Enterococcus faecalis (vancomycin-susceptible strains).
To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALVANCE and other antibacterial agents, DALVANCE should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
DALVANCE is contraindicated in patients with known hypersensitivity to dalbavancin.
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Serious hypersensitivity (anaphylactic) and skin reactions have been reported with glycopeptide antibacterial agents, including DALVANCE. Exercise caution in patients with known hypersensitivity to glycopeptides due to the possibility of cross-sensitivity. If an allergic reaction occurs, treatment with DALVANCE should be discontinued.
Infusion-related Reactions
Rapid intravenous infusion of DALVANCE can cause reactions, including flushing of the upper body, urticaria, pruritus, and rash.
Hepatic Effects
ALT elevations with DALVANCE treatment were reported in clinical trials.
Clostridium difficile-associated Diarrhea
Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including DALVANCE, with severity ranging from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.
Development of Drug-resistant Bacteria
Prescribing DALVANCE in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
ADVERSE REACTIONS
The most common adverse reactions in patients treated with DALVANCE were nausea (4.7%), headache (3.8%), and diarrhea (3.4%).
USE IN SPECIFIC POPULATIONS
Please see full prescribing information for DALVANCE at www.dalvance.com.
ABOUT TEFLARO®
TEFLARO was first approved by the U.S. FDA in October 2010 for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) due to designated susceptible pathogens. TEFLARO is a bactericidal cephalosporin with activity against both Gram-positive and Gram-negative pathogens. TEFLARO is indicated in adult and pediatric patients 2 months of age and older for the treatment of CABP, including cases caused by Streptococcus pneumoniae, and ABSSSI, including cases caused by methicillin-resistant Staphylococcus aureus (MRSA). TEFLARO is the first and only cephalosporin with activity against MRSA in ABSSSI. In clinical trials, TEFLARO was generally well-tolerated with an adverse event profile consistent with the cephalosporin class of antibiotics. TEFLARO has been administered in over 2.3 million days of therapy, treating more than 350,000 patients.
Allergan plc (formerly Forest Laboratories) obtained the worldwide rights (excluding Japan, where Takeda Pharmaceuticals holds rights) to TEFLARO in 2007 when it acquired Cerexa, Inc., a privately held biopharmaceutical company. In August 2009, Forest Laboratories and AstraZeneca (NYSE: AZN) entered into a definitive collaboration agreement to co-develop and commercialize ceftaroline fosamil in all markets outside the U.S., Canada and Japan.
INDICATIONS AND USAGE
IMPORTANT SAFETY INFORMATION
Contraindications
Warnings and Precautions
Hypersensitivity Reactions
Clostridium difficile-Associated Diarrhea
Direct Coombs' Test Seroconversion
Development of Drug-Resistant Bacteria
Adverse Reactions in Adults
Adverse Reactions in Pediatrics
Drug Interactions
Use in Specific Populations
Please also see the full Prescribing Information at www.TEFLARO.com.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.
Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan's website at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
CONTACTS:
Investors:
Lisa DeFrancesco
(862) 261-7152
Media:
Mark Marmur
(862) 261-7558
Fran DeSena
(973) 517-3132
SOURCE Allergan plc